Spots Global Cancer Trial Database for irinotecan liposome
Every month we try and update this database with for irinotecan liposome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | NCT06225622 | Metastatic Colo... | Irinotecan Lipo... Oxaliplatin 5-FU LV Bevacizumab Cetuximab | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | NCT06258642 | Small Cell Lung... | Irinotecan Lipo... Anlotinib | 18 Years - 75 Years | Fudan University | |
| SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer | NCT03732508 | Advanced Esopha... | Irinotecan lipo... SHR-1316 Fluorouracil | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | NCT06225622 | Metastatic Colo... | Irinotecan Lipo... Oxaliplatin 5-FU LV Bevacizumab Cetuximab | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors | NCT05086822 | Advanced Solid ... | Irinotecan lipo... | 18 Years - 65 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer | NCT03732508 | Advanced Esopha... | Irinotecan lipo... SHR-1316 Fluorouracil | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | NCT04390399 | Pancreatic Canc... | N-803 Aldoxorubicin H... PD-L1 t-haNK Nab-paclitaxel Gemcitabine Cyclophosphamid... 5-Fluorouracil Leucovorin SBRT Irinotecan lipo... | 18 Years - | ImmunityBio, Inc. | |
| A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors | NCT05086822 | Advanced Solid ... | Irinotecan lipo... | 18 Years - 65 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer | NCT06341309 | Metastatic Colo... | Irinotecan Lipo... Bevacizumab | 18 Years - 85 Years | West China Hospital | |
| Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | NCT06225622 | Metastatic Colo... | Irinotecan Lipo... Oxaliplatin 5-FU LV Bevacizumab Cetuximab | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer | NCT05969899 | Colorectal Canc... | FOLFIRI+Bevaciz... | 18 Years - 75 Years | Fudan University | |
| SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer | NCT03732508 | Advanced Esopha... | Irinotecan lipo... SHR-1316 Fluorouracil | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | NCT06258642 | Small Cell Lung... | Irinotecan Lipo... Anlotinib | 18 Years - 75 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
